Nachrichten zur Acorda Therapeutics Inc. Aktie

CHAPEL HILL, North Carolina--(BUSINESS WIRE)--Areteia Therapeutics, Inc. („Areteia“) gab heute bekannt, dass der Vorstand mit sofortiger Wirkung Donald J. Hayden,…

CHAPEL HILL, North Carolina--(BUSINESS WIRE)--Areteia Therapeutics, Inc. („Areteia“), ein Biotechnologieunternehmen im klinischen Stadium, das neuartige Entzündungs- und Immuntherapien entwickelt, mit…

SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical…

SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced…

SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…

SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…

VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP…

ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…

FRANKFURT, Deutschland--(BUSINESS WIRE)--Merz Therapeutics gab heute den erfolgreichen Erwerb von INBRIJA® (Levodopa-Pulver zur Inhalation) und (F)AMPYRA® (Fampridin) von Acorda Therapeutics,…

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…

PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a…

…

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported…

…

HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical…

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company…